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Abstract: This paper describes the significant advances in the treatment of childhood cancer 
and supportive care that have occurred over the last several decades and details how these 
advances have led to improved survival and quality of life (QOL) for children with cancer 
through a multidisciplinary approach to care. Advances in the basic sciences, general medicine, 
cooperative research protocols, and policy guidelines have influenced and guided the multidis-
ciplinary approach in pediatric oncology care across the spectrum from diagnosis through 
long-term survival. Two case studies are provided to highlight the nature and scope of multi-
disciplinary care in pediatric oncology care.
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Introduction
The trajectory of care for children with cancer includes diagnosis through treatment, 
including surveillance, rehabilitation, palliation, and end-of-life care.1 Progress in 
treatment of childhood cancer, once a nearly universally lethal disease, has led to an 
overall cure rate of nearly 80%.1 Advances in the cure rates for childhood cancer have 
paralleled the progress in supportive and palliative care for this population. 
The advances seen throughout the field can be attributed to the multidisciplinary nature 
of care delivery and research. This paper describes some of the major advances in the 
treatment of childhood cancer and supportive care that have occurred over the last 
several decades and how these multidisciplinary advances have led to improved sur-
vival and QOL for children with cancer.
The early years
Pediatric oncology emerged as a subspecialty in the years following World War II 
when Farber observed the benefits of chemotherapy for acute childhood leukemia.3 
Until then, general practitioners and pediatricians, in consultation with general 
surgeons, pathologists, and therapeutic radiologists, treated children with cancer, in 
which drug therapy consisted of single agents administered only to children with 
leukemia; children with solid tumors were not offered any systemic treatment.2 The 
science of pediatric oncology systemic therapy further advanced when Farber reported 
that remission was being achieved in children diagnosed not only with leukemia, 
but also with lymphoma and Wilms’ tumor.3 Wilbur reported that chemotherapy 
could effectively reduce the size of solid tumors to enhance the effectiveness of other 
treatment modalities such as surgery and radiation.4 These early successes were Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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the impetus for multidisciplinary therapy. Meadows pointed 
out that modern therapy for childhood cancer using multi-
agent and multimodal therapy began about 1970.5
Disease-specific success stories
Advances in the basic sciences, general medicine, coopera-
tive research protocols, and policy guidelines have influenced 
and guided the multidisciplinary approach in pediatric 
oncology care. The treatment of leukemia is a good example 
of the multidisciplinary cooperation necessary to develop 
the successful regimens currently available to children diag-
nosed with leukemia. The use of antimetabolite chemo-
therapy to treat childhood leukemia emerged as an effective 
therapy in the 1960s, but the success was short lived and did 
little to improve the overall survival.6 The next advances in 
the treatment of childhood leukemia came with the addition 
of multi-agent therapies, but, again, long-term remissions 
were elusive due to central nervous system (CNS) involve-
ment of the disease.7 The discipline of radiotherapy was 
incorporated to overcome this new obstacle and treatment/
prophylaxis of the CNS in children with leukemia was 
  initiated.8 The addition of CNS radiation made dramatic 
improvements to the length of remission of leukemia, but as 
survival improved the intellectual disadvantages for survivors 
of this therapy emerged. As clinicians worked on designing 
therapies that could adequately treat the CNS with minimal 
impact on cognitive function, advances in the laboratory 
sciences became significant in the field. Immunologists were 
the first to identify prognostic markers in leukemia cells that 
would later dictate the therapies used and this led to the risk-
based therapies used in today’s regimens.9–12 Risk-based 
therapy allows treatment to be tailored so that children with 
the highest risk of poor outcomes receive sufficient therapy, 
while those at lower risk have therapy minimized. Leukemia 
remains a multidisciplinary success story, utilizing 
  multi-agent, risk-based therapy and the prudent use of radia-
tion to boast cure rates in excess of 80%.13
Multidisciplinary approaches have led to similar advances 
in most childhood cancers. The surgery discipline has been 
responsible for important advances in the treatment of many 
solid tumors. Osteosarcoma is the most common type of bone 
tumor seen in children and its management illustrates the 
important contributions the surgical discipline can make.14 
Because osteosarcoma most frequently occurs in the extremi-
ties, it presents unique challenges for maintaining functionality 
without compromising cure. Limb salvage surgery is a crucial 
intervention necessary to insure optimal function for children 
and adolescents with this disease. Advances in surgical 
techniques, including state-of-the-art prostheses, allografts, 
and cadaver bone, have ensured complete removal of these 
tumors with good functional outcomes for   survivors.15 Surgi-
cal advances in diagnostic and resection procedures for solid 
tumors have been important in the overall survival and QOL 
in childhood cancer.16
Pediatric cancer centers
Optimal outcomes in childhood cancer are not only due to 
therapeutic advances but also reflect the influence of pub-
lished policy guidelines that have enhanced short-term and 
long-term outcomes for children and adolescents with cancer. 
Specifically, the published guidelines of the American Acad-
emy of Pediatrics for pediatric cancer centers was a major 
step forward for advancing the multidisciplinary care 
approach for children and adolescents with cancer.17,18 These 
guidelines, listed in Table 1, specify that a multidisciplinary 
team committed to providing an optimal level of the care for 
children and adolescents with cancer must exist and be 
functional in these centers. These centers house the collective 
expertise and networks of experienced researchers and a 
variety of health care professionals who recognize the 
Table 1 American Academy guidelines for multidisciplinary teams in pediatrics for cancer centersa
1. Board certified/eligible or equivalent pediatric hematologist/oncologist
2. Board certified pathologist(s) committed to handling specimens according to COG protocols
3.   Nurses with additional training in the management of children and adolescents with cancer and blood disorders, and documented in-house training 
in chemotherapy administration
4. Clinical research associates trained in data management support of cooperative research
5. Respiratory therapists with expertise in pediatrics
6. Anesthesiologist with expertise in the management of children
7. Radiologist with expertise in the management of children
8. Pharmacist with expertise in chemotherapy
9. Social worker with additional training in the management of children and adolescents with cancer and blood disorders
Note: aAdapted from the American Academy of Pediatrics. Guidelines for pediatric cancer centers: section on hematology/oncology policy statement on guidelines for 
pediatric cancer centers. Pediatrics. 2004;113(6):1833–1835.
Abbreviation: COG, Children’s Oncology Group.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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significance of randomized clinical trials as the most effective 
method for identifying more successful treatment strategies 
and who have the resources to evaluate new treatment 
modalities.18 These multidisciplinary teams offer a unique 
and the most effective approach to the early detection, 
accurate diagnosis, and appropriate treatment for various 
childhood cancer diagnoses.
Pediatric cancer centers with comprehensive multidisci-
plinary teams are often limited to developed countries and 
far fewer resources are available in underdeveloped areas of 
the world. It is expected that only 25% of children diagnosed 
with cancer in low- to middle-income countries will survive.19 
The creation of a multidisciplinary pediatric oncology unit, 
utilizing protocol-based therapy and local support has been 
shown to nearly double (from 32% to 63%) the 5-year event-
free survival in a region with otherwise limited resources.20 
In developed countries there is some controversy over the 
equality of the benefit of multidisciplinary care. For example, 
nearly every child treated for cancer in the USA can expect 
to receive treatment at a pediatric cancer center, yet racial 
differences in survival can still be observed.21 In these cir-
cumstances, multidisciplinary care alone may not be enough 
to overcome the environmental, social, and biological dif-
ferences among children with cancer.
The medical care and management of childhood cancer 
does not reside solely in the specialty disciplines at pediatric 
cancer centers. Primary care physicians in the community 
have an important role throughout the trajectory of childhood 
cancer care. The pediatrician is typically the first to evaluate 
symptoms associated with cancer; this is not an easy task, as 
many of the initial symptoms mimic common childhood 
illnesses. Fever, abdominal mass, lymphadenopathy, head-
ache, bone pain, and abnormal blood counts are associated 
with newly diagnosed childhood cancer; the expertise of a 
skilled practitioner is required to differentiate these symp-
toms from the numerous non-malignant conditions that have 
similar presentations.22 The pediatrician’s role does not end 
at diagnosis but continues throughout the treatment period 
to include the management of infection and treatment of side 
effects, as well as after-therapy care when monitoring for 
complications and ensuring appropriate growth and develop-
ment are vital components of care.22,23
The contributions of pediatric oncology nurses in the 
multidisciplinary care of children with cancer are well 
recognized and valued. Klein described an interdisciplin-
ary team should consist of practitioners from different pro-
fessions who share a common patient population and 
common patient care goals and have responsibility for 
complementary tasks.24 Specific outcome-based advances 
in pediatric oncology nursing practice have augmented the 
prescribed treatments determined through clinical trials to 
address some of the common side effects and complications 
of agents administered in these protocols. One such 
example is a comprehensive, multi-focused project 
embarked upon by the Oncology Division of the Children’s 
Hospital of Philadelphia to reduce chemotherapy errors.25 
A specific venture within this multifocal project was the 
implementation of the “Rapid Hydration Protocol.” This 
interdisciplinary research project was developed and tested 
by the pediatric oncology nursing staff. The outcomes of 
this evidence-based practice project were threefold: 
(1) decreased the time needed for hydration and the number 
of nurses involved in the institution of a chemotherapy 
protocol; (2) contribution made to having chemotherapy 
begin earlier in the day; and (3) systems in ordering che-
motherapy protocols were improved and decreased, which 
reduced handoffs.25
The development and implementation of a formal struc-
ture for nursing research within the Children’s Oncology 
Group (COG) structure was launched to enable more direct 
contributions of the nursing discipline to the scientific mis-
sion of this cooperative group.26 The strategic plan for this 
project was launched at the first State of the Science Summit 
for Pediatric Oncology Nursing Research on the campus 
of the National Institutes of Health in 2000. Four areas of 
research were identified: (1) the neurocognitive conse-
quences for the treatment team, (2) fatigue and related 
symptoms, (3) the coping efforts of patients/families/team 
and (4) self-care.27
One published study that addressed fatigue and related 
symptoms examined the effects of dexamethasone on sleep 
and fatigue in which the lead investigator was a pediatric 
oncology nurse-researcher.28 This investigation involved 
100 pediatric patients with low- or standard-risk acute lym-
phoblastic leukemia (ALL) enrolled in one of three COG 
protocols at three different institutions. It was reported that 
dexamethasone treatment during continuation therapy for 
childhood ALL significantly and adversely altered sleep and 
fatigue, confirming that sleep and fatigue are behavioral 
responses to dexamethasone.28 The next step, based on these 
findings, is to examine the relationship between these behav-
ioral indicators and the biologic indicators of individual 
responsiveness to dexamethasone to identify pediatric 
patients with ALL who will be the most sensitive to dexam-
ethasone treatment, thereby allowing clinicians to design 
optimal dosing schedules for individual patients.28Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Despite these growing efforts, very few outcome-based 
studies to direct psychosocial care interventions for children 
and their families currently in treatment for cancer have been 
conducted. This is of great concern because pediatric oncol-
ogy nurses provide significant psychosocial care to these 
patients. In a review of the trajectory of pediatric cancer 
research, Reaman noted that psychosocial and biobehavioral 
research on outcomes is missing in cooperative group 
  studies.29 A major contributing factor to the lack of psycho-
social and biobehavioral research using the cooperative group 
mechanism is limited restricted resources. Studies investigat-
ing psychosocial outcomes and biobehavioral interventions 
must compete with both clinical trials focused on survival 
improvements for participant enrollment for resources and 
group support for investigator time.29
In his review of the history of pediatric cancer research, 
Reaman noted that, to date, the bulk of therapeutic research 
in pediatric cancer accomplished with controlled clinical 
trials has focused on survival.29 Outcomes-based nursing 
research and subsequent nursing care for childhood cancer 
survivors have reflected these research efforts. Ruccione 
described the rich heritage in cancer survivorship research 
and outcomes-based clinical care, which was pioneered by 
the discipline of pediatric oncology and has had pediatric 
oncology nurses at the forefront of survivorship clinical 
care, research, and education for more than 30 years.30 
Ruccione chronicled these accomplishments and high-
lighted milestones in outcomes-based clinical nursing care 
for survivors of childhood cancer by decades. Specifically, 
in the 1970s and 1980s, the establishment and growth of 
specialized long-term follow-up programs and the active 
involvement of nurses as members of cooperative group 
study committees in designing risk-adjusted therapy pro-
tocols aimed at minimizing late effects without decreasing 
survival were achieved.30 In the 1990s and into the 2000s, 
publications by pediatric oncology nurses about the late 
effects and risk-based follow-up care models of care for 
health care professionals and for the pediatric cancer sur-
vivor population were produced and disseminated.30 In the 
2000s, a collaborative effort between the COG Nursing 
Discipline and the Late Effects Committee produced risk-
based follow-up guidelines, a directory of services, and a 
resource guide, as well as launching several research 
protocols.30
QOL and multidisciplinary care
Health-related quality of life (HRQOL) is important for 
assessing the successful treatment of childhood cancer. 
HRQOL is a multidimensional construct that includes the 
impact of childhood cancer on the physical and psychosocial 
aspects of daily life for patients and families. Important 
components of HRQOL that have been identified during 
treatment include pain, nausea/vomiting, anxiety, concerns 
about communication, changes in body appearance, and 
cognitive dysfunction.31 While no studies were identified that 
specifically evaluated the impact of multidisciplinary care 
on HRQOL in this population, it is clear that addressing these 
issues requires expertise, including symptom management 
and psychosocial support from medical and allied health 
professionals. Models for survivorship care have embraced 
the multidisciplinary model and its potential impact 
on HRQOL.32 Many of the morbidities associated with child-
hood cancer survivorship have been shown to impact 
HRQOL, and can include organ damage, cognitive impair-
ments, and psychosocial dysfunction.33–35 A multidisciplinary 
approach to the complex health care needs of childhood 
cancer survivors has been proposed to be an efficient way to 
deliver care that is beneficial to patients, providers, and 
institutions.22
Cooperative clinical trial groups
Perhaps no other phenomenon has influenced the multidis-
ciplinary approach to pediatric oncology care as much as 
the development and continued existence of pediatric oncol-
ogy clinical group trials. Cooperative group research is 
essential to success in areas such as childhood cancer, where 
relatively small incidence rates require multi-institutional 
  collaboration. Reaman noted that the pediatric clinical trials 
groups have a highly systematic and organized approach to 
the investigation of treatment strategies for children and 
adolescents with cancer through hypothesis-driven clinical 
trials using a multi-center approach.32 Prior to the establish-
ment of cooperative groups, only Phase I or Phase II clinical 
trials using single agent therapy existed. Multi-agent thera-
pies were begun in Phase III clinical trials through coopera-
tive research groups and have accelerated the advances in 
treatment success.2
The first cooperative group in pediatric oncology was 
the Children’s Cancer Group (CCG). The CCG was founded 
in 1955 with federal government funding by the National 
Cancer Institute (NCI). The CCG was a multi-institutional 
cancer research organization composed of 112 member 
institutions in the USA, Canada, and Australia. The overall 
goals of the CCG were to improve survival and QOL for 
cancer patients and conduct therapeutic trials in multidisci-
plinary fields. The CCG served as a base from which to Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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conduct childhood cancer research through a team approach, 
including the diagnosis, treatment, and supportive care for 
children with cancer.37
Meadows identified landmarks in pediatric oncology by 
decade from the 1970s through the 1990s and linked these 
milestones to the efforts and outcomes of cooperative clinical 
trial groups.5 Landmarks in the 1970s included recognition 
that cure was possible, proliferation of randomized clinical 
trials, and use of effective multimodality therapy.5 Treatment 
and advances in the 1980s included tailoring therapy to risk 
factors, defining late effects, using lower radiation doses, 
and substituting effective drugs for radiation.5 The 1990s 
sentinel events in pediatric oncology, identified by Meadows, 
were the understanding of the relationship of dose to late 
effects, distinguishing research from clinical care, and 
initiating efforts to track and educate survivors. Additional 
contributions from these early cooperative research groups 
were the development of criteria for evaluation of response 
to therapy and the emergence of the biostatistician as an 
integral member of the research team.
Following the establishment of CCG, three other pedi-
atric oncology clinical trials groups were formed: the 
Pediatric Oncology Group, the National Wilms’ Tumor 
Study Groups, and the International Rhabdomyosarcoma 
Study Group. In 2000, the Children’s Oncology Group 
(COG) was established through the merger of these four 
cooperative clinical trials groups with the goal of conserving 
resources and increasing accrual rates so that important 
clinical questions could be more quickly answered. It is 
estimated that a member institution of COG treats 90% of 
children diagnosed with cancer in the USA.38 To further 
validate the effectiveness of a multidisciplinary care in 
pediatric oncology, the COG has established guidelines for 
comprehensive pediatric hematology/oncology programs. 
The guidelines for required on-site personnel and on-site 
services are listed in Table 2.
Supportive and palliative care
Supportive and palliative care plays a crucial role in the 
successful management of childhood cancer. Infection, 
nausea/vomiting, and pain are three areas in which sup-
portive care has experienced significant advances from a 
multidisciplinary approach. The morbidity and mortality 
associated with infection during treatment of childhood 
cancer remain serious obstacles. Nearly 3% of children with 
fever and neutropenia during cancer therapy are expected 
to die of sepsis, although progress in infection control has 
dramatically decreased morbidity and mortality during 
childhood cancer treatment.39 Bacterial, viral, and fungal 
infections pose risks to the child with cancer and the devel-
opment of new and more effective pharmacologic options, 
especially anti-fungal and anti-viral agents, have dramati-
cally decreased the morbidity and mortality associated with 
these infections.40,41 Most recently the identification of 
Table 2 Required on-site services for the COG membershipa
  1. Pediatric unit, ie, personnel trained in taking care of children even if beds are in an adult unit
  2. intensive care unit with the ability to treat critically ill children
  3. Outpatient clinic for the acute and chronic care and treatment of children and adolescents with cancer
  4. Computed axial tomography
  5. Ultrasonography
  6. Pharmacy with capability of storage, accurate preparation, dispensing, and accounting for investigational drugs, and other antineoplastics
  7. Anatomic pathology services necessary for the immediate handling of specimens:
   • Ability to perform and interpret rapid frozen sections
   • Ability to rapidly freeze specimens for storage
    Laboratory services necessary for the care of critically ill children that must be available 24 hours a day:
   • Ability to perform routine blood gas, clinical chemistry, hematology, and coagulation assays on small samples
   • Availability of therapeutic apheresis
   • immediate interpretation of organism stains
  8. Capabilities to provide appropriate isolation for patients with severe immunosuppression
  9. expertise available to determine the need to deliver and monitor total parenteral nutrition for critically and chronically ill children and adolescents
10. Pain management and sedation guidelines
11. Long-term follow-up services for survivors of pediatric cancer
12. Data collection and transfer systems to support clinical trials programs:
   • internet access at the institution
   • Individual email accounts for all COG members
   • At minimum, Windows XP (or Mac), 64 MB RAM, 15˝ monitor, access to a printer
Note: aAdapted from Children’s Oncology Group.64
Abbreviation: COG, Children’s Oncology Group.Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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children at highest risk for sepsis has been an important 
development and has led to early and aggressive treatment 
for the most vulnerable oncology patients.42,43
Other important advances in the prevention and treatment 
of infection in the childhood cancer population can be attrib-
uted to nursing care and research. Nurses are primarily 
responsible for the progress in patient/family education that 
ensures that techniques for preventing infection are followed 
and that early signs of infection are managed appropriately 
inside and outside the hospital setting.44 In addition, nurse 
researchers have contributed to the progress made in moni-
toring immunosuppressed patients and procedures to reduce 
the bloodstream infections often associated with central 
venous catheters.44–46
Multidisciplinary advances have been made in other 
supportive care areas that have led to dramatic improve-
ment in QOL for children with cancer. Control of vomiting 
is one such area of significant achievement. Once only a 
handful of moderately effective agents were available to 
treat this side effect of cancer treatment in children. 
  However, in the late 1980s a new class of antiemetic, the 
5-HT3 antagonists, began to be studied in children receiving 
chemotherapy and led to complete or major control of 
vomiting in 87% of the children studied.47 Since these early 
studies, physicians and nurses have worked side by side 
to better define, measure, and control not only vomiting, 
but also the equally unpleasant side effect, nausea.48,49 
These efforts have led to valid measurement tools and 
multi-agent antiemetic regimens that minimize the impact 
of nausea and vomiting on QOL during childhood cancer 
treatment.50–52
Pain control is yet another critical component of sup-
portive care in childhood cancer. Children may experience 
pain across the continuum of cancer care. It may be the 
initial symptom of their disease, a side effect of treatment, 
associated with procedures, or a symptom in the end-of-life 
phase for those who are not cured of their disease. Once 
again, a multidisciplinary approach is necessary to tackle 
this complex and serious threat to QOL. In the mid 1990s 
the World Health Organization (WHO) consulted experts 
in anesthesiology, neurology, nursing, oncology, pediatrics, 
pastoral care, and psychology to develop the Cancer Pain 
Relief and Palliative Care in Children consensus   guidelines.53 
These guidelines provide a ladder approach to pain manage-
ment using progressively stronger analgesic agents while 
recognizing the importance of nondrug therapies. Since this 
time, the WHO analgesic ladder has been used to study and 
reduce the pain associated with childhood cancer throughout 
the world.54,55
Complementary and alternative 
medicine
The use of complementary and alternative medicine (CAM) 
in conjunction with standard medical treatment is an emerg-
ing integrative approach in the care of oncology patients.56 
This integrative approach seeks to improve the supportive 
care available to patients while also determining through 
scientific clinical trials which adjuvant CAM therapies are 
medically sound, effective, and compatible with standard 
chemotherapy and radiation.57 Among pediatric oncology 
patients, CAM mind–body interventions are most often used 
as supportive care therapies to relieve symptoms, reduce side 
effects of treatment, and cope with the emotional aspect of 
living with a life-threatening disease.58 The interventions 
include hypnosis for reducing pain, anxiety, nausea, or 
vomiting,58,59 and music therapy and massage for improving 
mood states, anxiety, and symptom distress.57
With the increased use of CAM among pediatric oncology 
patients, investigations about its prevalence, safety, and 
effectiveness have emerged. Bishop and colleagues con-
ducted a systematic review of published studies from 1975 
to 2005, which included 28 studies with survey data to sum-
marize the current evidence on the prevalence of CAM 
among children with cancer.60 The total sample size across 
all 28 studies included 3526 pediatric oncology patients in 
whom the prevalence of CAM usage ranged from 6% to 91%. 
In contrast to what was reported by Post-White,57 Bishop and 
colleagues reported that herbal remedies were the most often 
reported CAM modality used for these children, followed 
by diets/nutrition and faith healing.60
The COG has made a major commitment to CAM 
research in childhood and adolescent cancer, beginning with 
studies of CAM in the area of supportive care.61 The first 
randomized, double-blind, placebo-controlled clinical trial 
initiated in 2004 by COG assessed the efficacy of Traumeel-S® 
(Heel, Inc, Albuquerque, NM), a homeopathic remedy made 
from plant extracts for the prevention and treatment of 
mucositis in children undergoing stem cell transplantation.61 
Post-White, Hawks, O’Mara, and Ott cited that the future 
directions in moving the CAM research agenda forward for 
children with cancer include: determining the safety, efficacy, 
and outcomes of individual CAM interventions, establishing 
safe dosages for children, and determining potential mecha-
nisms of action and interactions with medical treatment.62Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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Survivorship
The multidisciplinary approach in pediatric oncology extends 
to the care of childhood cancer survivors. The Institute of 
Medicine’s (IOM) report entitled Childhood Cancer Survi-
vorship: Improving the Care and Quality of Life recognizes 
that the treatment of childhood cancer is one of oncology’s 
great success stories.1 The IOM report also highlights that 
the unintended consequences of this success are not widely 
recognized. Intensity and complexity of treatment protocols 
and increasing survival rates among children and adolescents 
diagnosed with cancer has led to an increased awareness of 
the need to monitor and treat the long-term complications of 
these therapies. It is estimated that two-thirds of survivors 
will have at least one long-term complication and one-fourth 
will have a severe or life-threatening complication.1 These 
long-term complications have the potential to negatively 
affect not only the health status, but also the QOL for 
  survivors. Zebrack and Zeltzer recognized that survivorship 
data provide little information about the QOL expected, 
enjoyed, or endured by these individuals.63 The IOM report 
identified health status and QOL as essential treatment out-
comes for this population, who require a multidisciplinary 
approach to care. The Association of Cancer Online 
Resources now lists 53 comprehensive follow-up programs 
for childhood cancer survivors. The Association of Cancer 
Online Resources criteria required to be considered a com-
prehensive follow-up program include the requirements that 
the program: have a dedicated time and place for the survivor 
clinic to take place; meets at least twice a month; is staffed 
by a doctor with experience in the late effects after treatment 
for childhood cancer; has a nurse coordinator; and offers 
state-of-the-art screening for individuals’ risks of late effects, 
referrals to appropriate specialists, and wellness education.64 
In addition, CureSearch (associated with COG), provides 
information on 146 participating institutions that provide 
services for childhood cancer survivors and membership in 
COG requires that services be available for survivors.65
Multidisciplinary care for childhood cancer survivors has 
also been supported by research findings from the Childhood 
Cancer Survivors Study (CCSG). Established in 1993, the 
CCSG is a National Cancer Institute-funded cohort for the 
study of the long-term morbidity and mortality associated 
with the treatment of childhood cancer. Data are collected 
from a 26-member consortium of clinical pediatric centers 
in the USA and Canada; the database includes more than 
14 000 survivors and 3700 sibling controls. Publications 
resulting from CCSG data have addressed clinical practice 
issues, ranging from health care utilization, health behaviors, 
health status, chronic health conditions, psychosocial and 
QOL factors, second malignancies, endocrine and reproduc-
tive outcomes, to late mortality.66
The Long-term Follow-up Guidelines published by COG 
are yet another example of multidisciplinary progress for 
childhood cancer survivors.67 The guidelines, first developed 
in 2002, provide information on 136 therapeutic exposures, 
and 101 screening recommendations. They were developed 
by 18 multidisciplinary task forces that included physicians, 
physical therapists, nurses, audiologists, patient advocates, 
epidemiologists, social workers, and psychologists. 
  Recommendations are based on scientific evidence and the 
collective experience of experts in the area. They are regularly 
updated to reflect new evidence in the literature. The goals 
of these guidelines are to promote healthy lifestyles, suggest 
appropriate ongoing monitoring, facilitate early detection of 
complications, and allow for timely interventions.
Case studies
This first case study describes the initial experience of a 
previously healthy 4-year-old boy named Andrew, who has 
been referred to a pediatric cancer center for a consult to 
evaluate the diagnosis of childhood leukemia by his primary 
care pediatrician. Andrew is directly admitted to the pediatric 
oncology unit of a pediatric cancer center. Within several 
hours of being admitted, he is scheduled to have a bone mar-
row aspirate and biopsy, as well as a spinal tap to confirm 
the diagnosis. This initial treatment intervention involves a 
multidisciplinary team approach involving a member of the 
medical oncology team, a pediatric oncology nurse, and a 
child life therapist. The oncologist and the pediatric primary 
nurse provide the family with the necessary education about 
the procedure. Likewise, the nurse and the child life therapist 
use therapeutic play procedures before, during, and after the 
procedure to educate Andrew and address his fears and 
concerns. The specimens obtained from the procedure are 
then taken to an on-site lab dedicated to the care of pediatric 
oncology patients and examined by laboratory technicians 
specially trained in the examination of specimens for child-
hood cancer. Following the confirmation of the diagnosis of 
childhood leukemia, a parent meeting is scheduled to share 
with Andrew’s parents the diagnosis and plan of care. This 
meeting involves Andrew’s primary oncologist, his primary 
nurse, and a social worker. While this meeting is occurring, 
a pharmacist with specialized training in chemotherapy 
agents is dispensing the protocol’s chemotherapy. In addition, Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
178
Cantrell and Ruble
the pediatric surgery department has been consulted for 
placement of a central venous catheter.
Andrew’s treatment is a risk-based therapy protocol based 
on gender, age, initial presenting white blood cell count 
(WBC), and the morphological, immunological, and genetic 
subtype classifications of his disease. Based on Andrew’s age 
of 4 years, his initial WBC count of 22 000/mm3 and favor-
able marrow cytogenetic finding of hyperdiploidy .50; t 
(12;21) he is considered to be standard-risk precursor B-cell 
ALL. Andrew is placed on a COG protocol that stratifies 
treatment for children with leukemia based on risk at diag-
nosis in which he will not receive anthracycline during his 
initial 28-day treatment plan. This initial treatment plan 
includes the following drugs and schedule: cytarabine 
intrathecally (IT) on Day 1, vincristine IV on Days 1, 8, 15, 
and 22, dexamethasone – IV or orally – twice daily on Days 
1 through 28, pegaspargase intramuscularly (IM) on Day 4, 
5, or 6, and methotrexate IT on Days 8 and 29.
In the first week of this initial plan, Andrew also receives 
supportive care therapy to stabilize his physiological pro-
cesses with a focus on his immune and hematological 
functioning. His therapy includes intravenous fluids, blood 
product transfusions, and vigil assessments of his vital signs 
and complete blood cell count (CBC) results. In addition to 
these supportive treatment measures, Andrew and his family 
receive psychosocial supportive care and are introduced to 
the following members of the treatment team and their spe-
cific roles.
•	 Pediatric oncology nurses. These specialized professional 
nurses provide care, support, and education to children 
and their families who have a variety of cancer diagnoses. 
Some institutions assign patients and their families a 
primary nurse who will serve as a consistent presence 
throughout the duration of their treatment. Andrew and 
his family also may have care needs that require the 
expertise of the nursing staff from the pediatric intensive 
care unit, the pheresis center, physical rehabilitation unit, 
and the outpatient oncology clinic.
•	 Physicians. Andrew’s family can expect to meet their 
primary oncologist who will see them as outpatients. 
They will also meet oncology fellows and residents at 
various points along their treatment.
•	 Nurse practitioner. These advanced practice nurses col-
laborate with the medical team to provide and coordinate 
the ongoing care of Andrew.
•	 A social worker. Social work professionals assigned to 
the pediatric oncology department assist Andrew’s family 
through the financial and social issues of having a seri-
ously ill child, and are members of the psychology team. 
Some centers have specific psychological support 
programs while others have psychologists and psychia-
trists available on an as-needed basis.
•	 Members of the child life team. These individuals, with 
training in child development or having an earned degree 
in child life therapy, are introduced to Andrew and his 
family early into their treatment and continue to care for 
Andrew’s therapeutic play needs throughout the hospital 
stay and on return hospitalizations. Members of the child 
life team vary from center to center, but can include 
child life specialists, art and music therapists, hospital-
based schoolteachers and recreational therapists.
This next case study describes a 25-year-old female, 
Christy, who is long-term survivor of Hodgkin’s disease. 
Christy was diagnosed at age 16 years when she presented 
with cervical lymphadenopathy and on work-up was found 
to have mediastinal involvement. Her treatment included 
Adriamycin 200 mg/m2, Bleomycin 80 units/m2, Vinblas-
tine, Dacarbazine, and 2100 cGy radiation to the neck and 
mantle fields. She is followed in a survivorship program 
on a yearly basis. Christy is at risk for late cardiac com-
plications, including diminished left ventricular function, 
pericarditis, valvular disease, early coronary artery disease, 
and arrhythmia. She requires yearly follow-up for cardiac 
signs/symptoms and every 2 years has echocardiogram 
(EKG) and lipid profile/fasting glucose. Patient education 
includes diet and exercise to reduce risk of cardiac 
  complications. Her radiation and Bleomycin put her at risk 
for late pulmonary compromise including fibrosis, inter-
stitial pneumonitis, and restrictive/obstructive lung disease. 
She is evaluated yearly for pulmonary symptoms and has 
had a baseline pulmonary function test including diffusing 
capacity of the lung for carbon monoxide (DLCO) and 
spirometry. She receives counseling on good pulmonary 
hygiene (eg, smoking cessation) and appropriate vaccina-
tions (Influenza and Pneumoccal), which she obtains at her 
primary carer.
Christy is also at risk for a second malignancy, most 
notably secondary breast cancer due to her chest irradiation. 
She was instructed on self-breast exam upon entry to the 
survivorship program, and at 25 she began monitoring 
yearly with mammogram and breast magnetic resonance 
imaging (MRI). During her first exam, she was noted to 
have a density in the left breast and was referred for further 
radiologic evaluation with ultrasound. The density was Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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ultimately biopsied and pathology confirmed benign fibrotic 
changes. She is now followed in a high-risk breast program 
with increased screening and exams. Christy’s thyroid was 
in the radiation field, which puts her at risk for thyroid 
dysfunction. She is monitored yearly with physical exam 
and thyroid function tests; 2 years ago, she was noted to 
have an elevated thyroid-stimulating hormone (TSH) and 
started on thyroid supplementation to decrease her risk of 
developing nodules or malignancy. In addition, a social 
worker evaluates Christy yearly for any psychosocial 
sequelae of therapy.
Challenges and future directions
A major challenge facing childhood cancer and multidis-
ciplinary care is the cost of providing care and financing 
scientific advances in an era of diminishing health care 
funds. It is estimated to cost US$509 000 (1998) annually 
to treat a child with cancer; this cost includes physician, 
hospital, outpatient, and laboratory services.68 There were 
no studies identified that assess the cost effectiveness of 
multidisciplinary care but program evaluations that assess 
financial outcomes may become necessary to justify this 
approach.
The National Cancer Institute (NCI) is the primary fund-
ing agency for childhood cancer research in the USA. 
The NCI budget for pediatric cancer research in the fiscal 
year 2009 was US$192.8 million and includes multidisci-
plinary research in areas of diagnosis, treatment, biology, 
etiology, prevention, and outcomes research.69 Given the 
current economic climate, budget cuts threaten to diminish 
research funding and it is expected that there will be greater 
competition for research dollars. It may be necessary to 
incorporate health economists as part of the multidisciplinary 
team to insure resources are appropriately utilized to yield 
the greatest benefits.
Conclusion
This paper illustrates the importance of multidisciplinary 
care in pediatric oncology. There are few diseases as complex 
as childhood cancers, which have seen the proliferation of 
effective therapies over a matter of several decades. 
The impressive advances in the field would not be possible 
without the collaboration and cooperation of professionals 
across the scope of healthcare. Because of these advances, 
families who have to face the diagnosis of childhood cancer 
now have reason to be hopeful that their child will survive 
and go on to have a good QOL.
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